TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04859621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
Study: NCT05256134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as per the dosing schedule described in the Arm description.
Study: NCT05841303
Drug: Vit C
Normalized name: M-Vit Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vit c is proven to be an anti-inflammatory and antioxidant agent. also play a great role in collagen biosynthesis (collagen type I), as it helps in fibroblasts proliferation. It reduces the potentiality of scaring via inhibiting cross-linking of collagen fibers and fibrosis. It acts as a cofactor in hydroxyproline synthesis to produce collagen type IV and improves endothelial cell vitality and function..
Study: NCT06348706
Drug: Dipeptidyl peptidase 4 (DPP-4) inhibitor
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group received Dipeptidyl peptidase-4 (DPP-4) inhibitors supplementation in a dose of 50 mg with main meal for 6 months.
Study: NCT05477498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of placebo solution administered as normal saline (0.9% weight/volume (w/v) NaCl) by intravenous injection as per the instructions for active treatment.
Study: NCT03698448
Drug: OligoG Dry powder for inhalation
Normalized name: capryl oligoglucoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 capsules Dry Powder for Inhalation, BID
Study: NCT06013839
Drug: talfirastide
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA127 (talfirastide) is a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II).
Study: NCT05199519
Drug: IBI345
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI345 CAR-T cell injection by intravenous infusion
Study: NCT06610903
Drug: Hemay005
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the first cycle, 15mg (1 tablet/person) was given on an empty stomach for Hemay005-T1 or Hemay005-T2, and the second cycle was crossed over
Study: NCT06193889
Drug: Standard lymphodepletion regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lymphodepletion regimen
Study: NCT05934955
Drug: Placebo matching BI 1839100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 1839100
Study: NCT06611007
Drug: embolization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand arterial embolization with Lipiodol in emulsion with iodinated contrast agent
Study: NCT05116462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml D1 IV Q3W
Study: NCT05472662
Drug: Placebo 152a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pressurised metered-dose inhaler (pMDI) formulated with the 152a propellant
Study: NCT05472662
Drug: Placebo 134a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pressurised metered-dose inhaler (pMDI) formulated with the 134a propellant
Study: NCT05499013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium chloride, solution for injection
Study: NCT06297954
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo 10 ml IV in a single dose prior to randomization.
Study: NCT04919863
Drug: NTP42:KVA4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.
Study: NCT04919863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.
Study: NCT04860063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomly assigned to the Placebo group will be provided with placebo administrated per os three times a day for six months
Study: NCT04856150
Drug: Q-1802
Normalized name: Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-1802 will be administered intravenously.
Study: NCT05352347
Drug: NuSepin® 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NuSepin® 0.2 mg/kg in 100mL NS bid
Study: NCT05352347
Drug: NuSepin® 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NuSepin® 0.4 mg/kg in 100mL NS bid
Study: NCT05352347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) 100mL bid
Study: NCT05145179
Drug: SSGJ-705
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1, 1, 3, 6, 10, 15 or 20mg/kg, IV, Day 1, 8, 15 of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first. Every 4 weeks a treatment cycle.
Study: NCT04964518
Drug: APG 2575 ramp up arm
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG2575 ramp up + Azacitidine
Study: NCT06385561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered orally twice daily.
Study: NCT05250648
Drug: complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the arm with HIPEC, this will be performed with Mytomicin C, at a dose of 35 mg/m2 in peritoneal dialysis solution (2 liter/m2) for 90 minutes, with dose fractionation: 50% min 0, 25% min 30, 25% min 60
Study: NCT00081536
Drug: Aroplatin (Liposomal NDDP) in combination with capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05531097
Drug: HSK31679
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple oral doses of HSK31679
Study: NCT05531097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT06746311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, containing no active ingredient, administered subcutaneouly
Study: NCT05967052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06504420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Placebo 1.5mg/d for first 24 weeks and Sirolimus 1.5mg/d for next 24 weeks in addition to their ongoing APS treatment regimen
Study: NCT04938323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: .1 mL of diluent (saline) given intradermally at baseline
Study: NCT06086613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort).~In Part B, participants will receive multiple doses of placebo administered as a SC injection.
Study: NCT06613009
Drug: IBI3009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3009)
Study: NCT06213935
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: after spinal anesthesia, norepinephrine will be injected intravenous as bolus at 0.05 μg/kg, followed by norepinephrine infusion at a rate of 0.05 μg/kg.min to prevent post spinal hypotension
Study: NCT05712421
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine
Study: NCT04051801
Drug: Dose Escalation of Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose levels of the cohorts will be increased step wise
Study: NCT04830020
Drug: HMW-HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerolized administration b.i.d.
Study: NCT06128070
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04729309
Drug: [12C] RO7049389
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral \[12C\] RO7049389.
Study: NCT04729309
Drug: [13C] RO7049389
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV \[13C\] RO7049389.
Study: NCT04729309
Drug: [14C] RO7049389
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an oral suspension of \[14C\] RO7049389.
Study: NCT05321511
Drug: Ovitrelle® (hCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adminsitration of coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
Study: NCT05321511
Drug: Decapeptyl 0.1 mg® (a-GnRH) and Ovitrelle® (hCG) used together
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adminsitration of triptoreline acetate 0.2 mg and coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
Study: NCT04849065
Drug: Placebo / Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)
Study: NCT03184155
Drug: Sterile Saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus of intracoronary sterile saline injection prior to PCI followed by an additional 2-4 doses of sterile saline depending on complexity of PCI
Study: NCT05607641
Drug: Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Study: NCT05496335
Drug: AGN-151586
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injection
Study: NCT05496335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injection
Study: NCT00000723
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000723
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05297695
Drug: Triple therapy for H. pylori infection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy for H. pylori infection (Esomeprazole, Amoxicillin, and Clarithromycin) for two weeks
Study: NCT05980195
Drug: Standard medical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after stenting).~Other Name: Dual antiplatelet therapy for 3 months
Study: NCT03415061
Drug: Regular Insulin, Human 100 UNT/ML
Normalized name: regular insulin, human 100 UNT/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
Study: NCT03415061
Drug: Normal Saline Flush, 0.9% Injectable Solution
Normalized name: Normal Saline Flush, 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
Study: NCT05217719
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously. The duration of saline will be 7 days.
Study: NCT04706286
Drug: CKD-501, D759, D150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition
Study: NCT04706286
Drug: CKD-393 0.5/100/1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition
Study: NCT06015243
Drug: GR1802 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
Study: NCT04715932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
Study: NCT05033093
Drug: Root Canal Sealants
Approvals — FDA: no, EMA: no, PMDA: no
Description: it is planned to conduct the research described below, on the effect of calcium silicate-based (iRoot SP), silicone-based (GuttaFlow Bioseal) and rezin-based (AH Plus) sealer on postoperative pain
Study: NCT05219084
Drug: intra-articular hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml; of normal; saline were injected inside the hip joint
Study: NCT05607641
Drug: Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Study: NCT05219084
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: hip denervation and intra-articular hydration were conducted together
Study: NCT05219084
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal; saline was injected subcutaneously
Study: NCT05201352
Drug: trifluridine/tipiracil + XB2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: trifluridine/tipiracil every 28 days + XB2001 1000mg intravenous infusion every 2 weeks
Study: NCT05201352
Drug: trifluridine/tipiracil + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: trifluridine/tipiracil every 28 days + Placebo intravenous infusion every 2 weeks
Study: NCT00006199
Drug: R115777 (farnesyl transferase inhibitor)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04060316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is given as a nasal spray using an atomizer
Study: NCT05607641
Drug: Neospastil, solution for injection then Neospastil, film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III).~Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day.
Study: NCT06399809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be matched to the Fisetin intervention
Study: NCT05009680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered orally twice a day
Study: NCT05608980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily eyelid wipes for 2 weeks
Study: NCT04720131
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle)
Study: NCT03877991
Drug: CBD-LNL capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: A capsule containing Cannabidiol dissolved in self nano emulsifying formulation
Study: NCT03877991
Drug: CBD powder form capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder of Cannabidiol filled in a hard gelatin capsule, without formulation.
Study: NCT05133791
Drug: Annexin A5
Normalized name: Annexin A5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annexin A5 coupled to IRDye800CW as a potential treatment for RVO
Study: NCT04602715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Control
Study: NCT05943821
Drug: Optional intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 26 weeks(+/-2 weeks) after the start of the intervention, the efficacy of the treatment will be evaluated at the follow-up visit V2. Efficacy is defined as achieving a serum UA level below 5.0mg/dL for those with baseline levels \>5.0 to 7.0mg/dL or below 5.5mg/dL for those with baseline levels ≥7.0mg/dL. If insufficient therapy efficacy is noted, the initial allopurinol dose will be increased by 100mg (up to 300mg during V2). The dose may be increased by another 100mg at visit 3 and by another 100mg at the visit 4(up to 500mg during V4). In the placebo group, an appropriate preparation will be added so that the number of tablets corresponds to the group with the active substance.~This treatment will be continued until the end of the bservation. Patients who meet their UA target concentration at visit V2 or V3, or V4, and those who fail to meet their target concentration at visit V4, will not have their dosing changed until the end of the follow-up.
Study: NCT05868577
Drug: Corticosteroid injection (CSI) with local anesthetic (LA)
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PI will then administer the injection using an infracalcaneal needle peppering
Study: NCT06632561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pills one tablet daily for 6 months
Study: NCT05868577
Drug: Local anesthetic (LA) with Saline injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PI will then administer the injection using an infracalcaneal needle peppering
Study: NCT05873712
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04360096
Drug: ZYESAMI™ (aviptadil acetate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
Study: NCT04360096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Inhalation
Study: NCT00063219
Drug: MAC-321
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04913805
Drug: Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside
Normalized name: glycine propionyl-L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR)
Study: NCT04681066
Drug: CM-4620 Injectable Emulsion or CM-4620-IE
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.
Study: NCT05644600
Drug: AZD5055
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be administered AZD5055 as single oral dose on Day 1 in the fasted state.
Study: NCT06633471
Drug: Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.
Study: NCT04959591
Drug: intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental(pre): administration of IV acetaminophen
Study: NCT04959591
Drug: intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental(post): administration of IV acetaminophen
Study: NCT04959591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator: administration of normal saline
Study: NCT05366764
Drug: SAR443765
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection
Study: NCT05366764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection
Study: NCT05994001
Drug: cardonilizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: cardonilizumab:PD1 and CTLA-4 bispecific antibody
Study: NCT04576156
Drug: Best Available Therapy (BAT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-JAK-inhibitor treatment will be given, which may include but is not limited to hydroxyurea, thalidomide or an analog of thalidomide, interferon, danazol, hypomethylating agents, chemotherapy or radiotherapy.
Study: NCT05930457
Drug: 2.5-3.5mCi 64Cu-FAPI-XT117
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2.5-3.5mCi 64Cu-FAPI-XT117 injection.
Study: NCT05930457
Drug: 4.5-5.5mCi 64Cu-FAPI-XT117
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4.5-5.5mCi 64Cu-FAPI-XT117 injection.
Study: NCT00084032
Drug: Antiretroviral regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take any combination of FDA-approved ARV medications prescribed by their physician
Study: NCT05988632
Drug: Regular Human Insulin then Placebo
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin: 80 IU (administered intranasally) THEN Placebo: 0.9% saline solution (administered intranasally)
Study: NCT05988632
Drug: Placebo then Regular Human Insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 0.9% saline solution (administered intranasally) THEN Insulin: 80 IU (administered intranasally)
Study: NCT04565925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Lactose) TID for 4 weeks